Allysta Pharmaceuticals, Inc. Announces Initiation of Dosing in OASIS-1 Phase 2b/3 Clinical Trial (ALY688-301 Study) Evaluating the Efficacy and Safety of ALY688 Ophthalmic Solution in Dry Eye

Allysta Pharmaceuticals, Inc. Announces Start of Phase 1 Clinical Trial of ALY688-SR, a Novel First-in-Class Peptide that Targets Adiponectin Signaling

​

Allysta Pharmaceuticals, Inc. Announces Positive Preclinical Data in a NASH Model Demonstrating its Adiponectin Analogue ALY688 Reduces Liver Fat, Inflammation, and Fibrosis

​

Allysta Pharmaceuticals, Inc. Announces Positive Results from its Phase 1/2a Clinical Trial of ALY688 Ophthalmic Solution in Dry Eye Disease

​

Allysta Pharmaceuticals, Inc. Doses First Patient with ALY688 Ophthalmic Solution in Phase 1/2a Dry Eye Study

​

Allysta Pharmaceuticals, Inc. Raises Additional $5 Million in Series A Financing to Advance Novel Therapeutic for NASH

Allysta Pharmaceuticals, Inc. to Present at OIS@ASCRS

​

Allysta Pharmaceuticals, Inc. to Present New Results on ALY688 at the Annual Meeting of ARVO

Allysta Pharmaceuticals, Inc. Raises $15 Million in

Series A Financing to Advance Novel Therapeutic for Dry Eye Disease 

​

Allysta Pharmaceuticals, Inc. Doses First Patient in Phase 2A Study in Glaucoma

​

Data on Allysta Pharmaceuticals’ Lead Compound, ADP355, Presented at the Annual Meeting of ARVO in Baltimore MD

Poster presented by Prof KC Yoon, Chairman, Dept Ophthalmology, Chonnam University, Korea

​

Allysta Pharmaceuticals, Inc. to present at the QB3 – 2017 Life Science Pitch Summit

​

Allysta Pharmaceuticals, Inc. to present at the National Investment Banking Association Conference

​

Allysta Pharmaceuticals, Inc. to present at the Ninth Annual Biotech Showcase Conference in San Francisco

​